PEGYLATED INTERFERON REDUCES RELAPSES FOLLOWING BEPIROVIRSEN TREATMENT IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION ON NUCLEOS(T) IDE ANALOGUES: END OF STUDY RESULTS FROM THE PHASE 2b B-TOGETHER STUDY
Recommended Citation
Buti M, Heo J, Tanaka Y, Andreone P, Atsukawa M, Cabezas J, Chak E, Coffin CS, Fujiwara K, Gankina N, Gordon SC, Janczewska E, Komori A, Lampertico P, McPherson S, Morozov V, Niu J, Plesniak R, Poulin S, Ryan P, Sagalova O, Sheng G, Voloshina N, Xie Q, Yim HJ, Dixon S, Paff M, Felton L, Lee M, Greene T, Lakshminarayanan D, Plein H, Youssef A. PEGYLATED INTERFERON REDUCES RELAPSES FOLLOWING BEPIROVIRSEN TREATMENT IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION ON NUCLEOS(T) IDE ANALOGUES: END OF STUDY RESULTS FROM THE PHASE 2b B-TOGETHER STUDY. Hepatology 2023; 78:S49-S53.
Document Type
Conference Proceeding
Publication Date
10-25-2023
Publication Title
Hepatology
Abstract
Background: In the B-Clear study, bepirovirsen 300 mg for 24 weeks achieved hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA100 IU/mL and HBV DNA<90 IU/mL were randomised 1:1 to bepirovirsen 300 mg once-weekly (plus loading dose on Days 4 and 11) for 24 (Arm 1) or 12 (Arm 2) weeks, followed by up to 24 weeks of PegIFN 180 mcg once-weekly, with 24 (Arm 1) or 36 (Arm 2) weeks follow-up. Participants continued NA therapy. Primary endpoint: proportion of participants with HBsAg and HBV DNA
Volume
78
First Page
S49
Last Page
S53
